Drug dosing based on weight and body surface area: Mathematical assumptions and limitations in obese adults

Pharmacotherapy

Volumn 32, Issue 9, 2012, Pages 856-868

  Pai, Manjunath P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Allometry; Body surface area; Dosing; Fat free; Ideal; Lean; Obesity; Weight

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; AZTREONAM; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; COLISTIN; DAPTOMYCIN; ENROFLOXACIN; TELAVANCIN; VANCOMYCIN;

ADJUSTED BODY WEIGHT; ADULT; ADULTHOOD; ALLOMETRY; AREA UNDER THE CURVE; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BODY SIZE; BODY SURFACE; BODY WEIGHT; DOSAGE SCHEDULE COMPARISON; DOSE CALCULATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EXPOSURE; FAT FREE WEIGHT; HUMAN; KIDNEY FUNCTION; LEAN BODY WEIGHT; NEPHROTOXICITY; NONHUMAN; OBESITY; REVIEW; SIDE EFFECT; UNITED STATES;

ADULT; BODY SURFACE AREA; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG DOSAGE CALCULATIONS; HUMANS; OBESITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; UNITED STATES;

EID: 84867600008     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01108.x     Document Type: Review

References (75)

1. World Health Organization. Global database on body mass index: BMI classification. http://apps.who.int/bmi/index.jsp?introPage=intro-3.html. Accessed November 18, 2011.
2. Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kindey Dis 2010;17: e53-e62.
3. Devine B. Case study number 25 gentamicin therapy. Drug Intell Clin Pharm 1974;8:650-655.
4. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983;24:643-647.
5. James W. Research on obesity. London: Her Majesty's Stationery Office; 1976.
6. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005;44:1051-1065.
7. Du Bois D, Du Bois EF. Clinical calorimetry. Tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863.
8. Mosteller RD. Simplified calculation of body surfaced area. N Engl J Med 1987;317:1098.
9. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004;58:119-133.
10. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 2011;7:697-706.
11. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970;54:225-235.
12. Livingston EH, Lee S. Body surface area prediction in normalweight and obese patients. Am J Physiol Endocrinol Metab 2001;281:E586-E591.
13. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area. A height weight formula validated in infants, children and adults. J Pediatr 1978;93:62-66.
14. Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011;90:77-89.
15. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241.
16. Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev 2009;35:69-78.
17. Tanner JM. Fallacy of per-weight and per-surface area standards, and their relation to spurious correlation. J Appl Physiol 1949;2:1-15.
18. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:1883-1888.
19. AHFS. Drug information. Bethesda, MD: American Society of Health Systems Pharmacists; 2011.
20. Ogden CL, Fryar CD, Carroll MD, et al. Mean body weight, height, and body mass index, United States 1960-2002. Adv Data 2004;347:1-17.
21. Young JF, Luecke RH, Pearce BA, et al. Human organ/tissue growth algorithms that include obese individuals and black/ white population organ weight similarities from autopsy data. J Toxicol Environ Health A 2009;72:527-540.
22. 2 body surface area normalization: problems and implications. Clin Physiol Funct Imaging 2007;27:135-137.
23. Gorber SC, Tremblay M, Moher D, Gorber B. A comparison of direct vs. self-report measures for assessing height, weight and body mass index: a systematic review. Obes Rev 2007;8:307-326.
24. Godoy R, Goodman E, Levins R, Leonard WR. Anthropometric variability in the USA: 1971-2002. Ann Hum Biol 2005;32:469-486.
25. Komlos J, Lauderdale BE. The mysterious trend in American heights in the 20th century. Ann Hum Biol 2007;34:206-215.
26. Meazza C, Pagani S, Bozzola M. The pygmy short stature enigma. Pediatr Endocrinol Rev 2011;8:394-399.
27. Hirschhorn JN, Lettre G. Progress in genome-wide association studies of human height. Horm Res 2009;71(Suppl 2):5-13.
28. Alexander ND, Cousens SN, Yahaya H, Abiose A, Jones BR. Ivermectin dose assessment without weighing scales. Bull World Health Organ 1993;71:361-366.
29. Eknoyan G. Adolphe Quetelet (1796-1874)-the average man and indices of obesity. Nephrol Dial Transplant 2008;23:47-51.
30. National Institutes of Health. Health implications of obesity. National Institutes of Health Consensus Development Conference Statement. Ann Intern Med 1985;103:147-151.
31. Dembert ML, Jekel JF, Mooney LW. Weight-height indices and percent body fat among U.S. Navy divers. Aviat Space Environ Med 1984;55:391-395.
32. Garrow JS, Webster J. Quetelet's index (W/H2) as a measure of fatness. Int J Obes 1985;9:147-153.
33. Saito K, Nakaji S, Umeda T, Shimoyama T, Sugawara K, Yamamoto Y. Development of predictive equations for body density of sumo wrestlers using B-mode ultrasound for the determination of subcutaneous fat thickness. Br J Sports Med 2003;37:144-148.
34. Lee SY, Gallagher D. Assessment methods in human body composition. Curr Opin Clin Nutr Metab Care 2008;11:566-572.
35. Mahmood I. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci 2010;99:2927-2933.
36. West LJ, Pierce CM, Thomas WD. Lysergic Acid Diethylamide: its effects on a male asiatic elephant. Science 1962;138:1100-1103.
37. Vocci F, Farber T. Extrapolation of animal toxicity data to man. Regul Toxicol Pharmacol 1988;8:389-398.
38. Kleiber M. Body size and metabolic rate. Physiol Rev 1947;27 (4):511-541.
39. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: estimating the maximum safe starting dose in clinical trials for therapeutics in adult healthy volunteers. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2005.
40. Kolokotrones T, Savage V, Deeds EJ, Fontana W. Curvature in metabolic scaling. Nature 2010;464:753-756.
41. White CR. Physiology: there is no single p. Nature 2010;464:691-693.
42. Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992;36:318-325.
43. Han PY, Kirkpatrick CM, Green B. Informative study designs to identify true parameter-covariate relationships. J Pharmacokinet Pharmacodyn 2009;36:147-163.
44. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958;18:853-856.
45. Agutter PS, Tuszynski JA. Analytic theories of allometric scaling. J Exp Biol 2011;214:1055-1062.
46. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999;284:1677-1679.
47. Heymans O, Fissette J, Vico P, Blacher S, Masset D, Brouers F. Is fractal geometry useful in medicine and biomedical sciences? Med Hypotheses 2000;54:360-366.
48. Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother 2000;34(9):1066-1069.
49. Czerniawski AM. From Average to Ideal. The Evolution of the Height and Weight Table in the. United States, 1836-1943. Soc Sci Hist 2007;31:273-296.
50. Dulloo AG, Jacquet J, Solinas G, Montani JP, Schutz Y. Body composition phenotypes in pathways to obesity and the metabolic syndrome. Int J Obes (Lond) 2010;34(Suppl 2):S4-S17.
51. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008;294:F685-F696.
52. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988;84:1053-1060.
53. Pai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother 2011;55:4006-4011.
54. Mahmood I. Interspecies scaling of renally secreted drugs. Life Sci 1998;63:2365-2371.
55. Hu TM, Hayton WL. Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 2001;3:E29.
56. Martinez M, Mahmood I, Hunter RP. Allometric scaling of clearance in dogs. J Vet Pharmacol Ther 2009;32:411-416.
57. Paine SW, Ménochet K, Denton R, McGinnity DF, Riley RJ. Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab Dispos 2011;39:1008-1013.
58. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002;86:1297-1302.
59. Gao B, Klumpen HJ, Gurney H. Dose calculation of anticancer drugs. Expert Opin Drug Metab Toxicol 2008;4:1307-1319.
60. Chambers P, Daniels SH, Thompson LC, Stephens RJ. Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol 2012;23:748-753.
61. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and metaanalysis. Breast Cancer Res Treat 2010;123:627-635.
62. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 2004;22:648-657.
63. Corcoran GB, Salazar DE, Schentag JJ. Excessive aminoglycoside nephrotoxicity in obese patients. Am J Med 1988;85:279.
64. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001;111:528-534.
65. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503-4505.
66. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentrationtime profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-514.
67. Slover CM, Nkechi A, Barriere SL, Lu Q. Telavancin for treatment of complicated skin and skin structure infections in obese patients. Abstract L1-1491. Chicago, IL: Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011.
68. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177-180.
69. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010;50:1568-1574.
70. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004;48:2799-2807.
71. Worboys P, Barriere SL. Population pharmacokinetic analysis suggests minimal impact of obesity on telavancin (tlv) exposure. Abstract A1-1156. Chicago, IL: Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011.
72. Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol 2002;57:793-797.
73. Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos 2001;29:1136-1145.
74. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003;47:548-553.
75. Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol 2009;49:1071-1078.